Efficacy and Safety of DWC20155/DWC20156 Combination Therapy in Patients With Gastritis

Phase 3

Terminated

• Conditions: Gastritis
• Interventions: Drug: DWC20156; Drug: DWC20155; Drug: placebo of DWC20155; Drug: placebo of DWC20156

• Registration Number: NCT03184415
• Lead Sponsor: Daewoong Pharmaceutical Co. LTD.

Brief Summary

THe purpose of this study is to evaludate the Efficacy and Safety of DWC20155/DWC20156 Combination Therapy in Patients with Gastritis

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-06-09
• Study First Submitted QC: 2017-06-09
• Study First Posted: 2017-06-12
• Study Start: 2017-07-03
• Primary Completion: 2018-05-17
• Study Completion: 2018-05-17
• Status Verified: 2019-06
• Last Update Submitted: 2019-06-25
• Last Update Posted: 2019-06-26

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 230

Inclusion Criteria

• Male of female of at least 19 years old
• Patients diagnosed with acute or chronic gastritis by gastroscopy
• Patients with one or more erosions found by gastroscopy

Exclusion Criteria

• Patients with peptic ulcer and gastroesophageal reflux disease
• Patients with previous gastrointestinal surgery
• Patients with history of gastrointestinal cancer

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
DWC20155 Monotherapy	placebo of DWC20156	-
DWC20156 Monotherapy	DWC20156	-
DWC20156 Monotherapy	placebo of DWC20155	-
DWC20155/DWC20156 Combination Therapy	DWC20155	-
DWC20155/DWC20156 Combination Therapy	placebo of DWC20155	-
DWC20155 Monotherapy	DWC20155	-
DWC20155/DWC20156 Combination Therapy	DWC20156	-
DWC20155 Monotherapy	placebo of DWC20155	-

Primary Outcome Measures

Name	Time	Method
Improvement rates of stomach erosions by the endoscopy	At 2 weeks

Trial Locations

Locations (1)

Daewoong pharmatceutical; 🇰🇷 Seoul, Korea, Republic of